Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 12:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2425–2448 of 54,988 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Patient Clear all

Conditions: Mood Disorders, Bipolar Disorder, Major Depressive Disorder, Depression
Interventions: Patient Reported Outcomes; Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 5,716 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Lung Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer
Interventions: Exhaled Breath Sampling; Procedure
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Stanford, California

Conditions: Multiple Myeloma
Interventions: TAA-specific CTLs, TAA-specific CTLs- fixed dose; Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 3
States / cities: Houston, Texas

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: panitumumab, everolimus, fluorouracil, leucovorin calcium, oxaliplatin; Biological · Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Liver Cancer
Interventions: octreotide acetate; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Reticular Pseudodrusen (RPD), Age-Related Macular Degeneration
Interventions: Vitamin A Palmitate; Drug
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 50 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pulmonary Arterial Hypertension
Interventions: Beraprost sodium modified release; Drug
Lead sponsor: Lung Biotechnology PBC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Torrance, California • Pittsburgh, Pennsylvania • Dallas, Texas

Conditions: Lymphoma
Interventions: epratuzumab; Biological
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Advanced Cancer
Interventions: AGEN1777, a PD-1 inhibitor; Drug
Lead sponsor: Agenus Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 11
States / cities: Grand Rapids, Michigan • Southfield, Michigan • Cincinnati, Ohio + 4 more

Conditions: Aspiration, Respiratory
Interventions: pH monitoring, accelerometer monitoring; Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Validate Volumetric Absorptive Microsampling (VAMS) Assay
Interventions: Mitra Microsampler; Device
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 1 Year to 21 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Melanoma, Gastrointestinal Cancer, Breast Cancer, Ovarian Cancer, Pancreatic Cancer
Interventions: Peptide loaded dendritic cell vaccine; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Fasting, Delayed Gastric Emptying, Aspiration Pneumonia, Respiratory Aspiration of Gastric Content
Interventions: Gastric Ultrasound Baseline Scans, Acetaminophen Absorption Test (AAT), Gastric Ultrasound Serial Scans; Diagnostic Test
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 2 Years to 18 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Percutaneous Coronary Intervention, Coronary Artery Disease (CAD), Angioplasty
Interventions: PMX-60056; Drug
Lead sponsor: PolyMedix, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 3
States / cities: South Bend, Indiana • Detroit, Michigan • Rapid City, South Dakota

Conditions: Colorectal Cancer
Interventions: Minocycline, Placebo, Questionnaires, Sensory Test; Drug · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Severe Asthma, COPD, Non-CF Bronchiectasis, Cystic Fibrosis (CF)
Interventions: Hyperpolarized 129 Xenon; Combination Product
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: HIV Infections
Interventions: Indinavir sulfate, Lamivudine, Stavudine, Zidovudine, Didanosine; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Basal Cell Carcinoma
Interventions: Vismodegib 150 mg; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 21
States / cities: Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 17 more

Conditions: Chronic Heart Failure
Interventions: sacubitril/valsartan; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 9,230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Hypertension, Pulmonary
Interventions: Telephone concept elicitation interview; Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Covid-19 Vaccination
Interventions: Vaccine choice message, Vaccine choice + platform-framed message, Vaccine choice + HCP trust-framed message, Vaccine choice + reactogenicity-framed message; Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older
Enrollment: 1,300,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Heartburn
Interventions: Lanzoprazole; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 576 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 28
States / cities: Hoover, Alabama • Huntsville, Alabama • Sierra Vista, Arizona + 23 more

Conditions: Hepatic Encephalopathy
Interventions: Rifaximin SSD, Placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 517 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 90
States / cities: Homewood, Alabama • Chandler, Arizona • Sun City, Arizona + 70 more

Conditions: Malignant Melanoma, Neoplasm Metastasis
Interventions: CP-4055 (ELACYT); Drug
Lead sponsor: Clavis Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Search by objective public record fields.

Mood Patient Powered Research Network (MoodNetwork)

Breath Analysis for Evaluation of Radiation Exposure in Lung Cancer Patients Treated With Radiation

Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma

Everolimus, Fluorouracil, Leucovorin, Panitumumab, and Oxaliplatin in Treating Patients With Tumors That Did Not Respond to Treatment

Octreotide in Treating Patients With Locally Advanced or Metastatic Liver Cancer

Vitamin A Palmitate Supplementation in Patients With Reticular Pseudodrusen (RPD) and Delayed Dark Adaptation

A Multi-Center, Open-Label, Multiple Dose, Dose Finding Study Exploring the Safety and Tolerability of Beraprost Sodium Modified Release in PAH Patients

Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma

A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors

Continuous Supraglottic pH Monitoring in Prolonged Intubated Intensive Care Patients and High Risk Aspiration Intraoperative Patients

Tacrolimus Microsampling

Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous Cancer

Gastric Assessment of Pediatric Patients Undergoing Surgery

Reversal of Heparin in Patients Undergoing Percutaneous Coronary Intervention (PCI)

Phase II Study of Minocycline for Reducing Symptom Burden in Colorectal Patients

Evaluation of Ventilation Defects Downstream of Mucus Plugs in Patients With Muco-Obstructive Lung Disease

The Effectiveness of HIV RNA Viral Load Testing in Determining Treatment Type in HIV-Infected Patients

A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma

Sacubitril/Valsartan Treated Adult Patients With Chronic Heart Failure

Qualitative Research to Explore Treatment Preference in Pulmonary Arterial Hypertension (PAH) Subjects

Effect of Messaging on Pragmatic Outcomes Within an Integrated Healthcare System

Efficacy/Safety of Lansoprazole in Patients With Frequent Heartburn

Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis

Clinical Study of Previously Untreated Patients With Malignant Melanoma